Zydus gets FDA approval for skin, heart and acid reflux generics

Generics/News | Posted 15/02/2019 post-comment0 Post your comment

Zydus Cadila has received final approval from the US Food and Drug Administration (FDA) to market betamethasone dipropionate cream, 0.05%, a generic version of Diprolene® AF, and generic amlodipine and atorvastatin tablets (Caduet®). It has also received tentative FDA approval to market generic esomeprazole magnesium delayed-release capsules (Nexium®). This brings the total approvals of the Zydus group to 247, and it has so far filed over 330 abbreviated new drug applications (ANDAs) since the filing process commenced in the 2003‒2004 financial year.

52 MD002433

Betamethasone dipropionate cream is a strong corticosteroid used to treat corticosteroid-responsive dermatoses by relieving the inflammation and pruritus that often occurs with these conditions.

Amlodipine and atorvastatin tablets have been approved in the strengths of 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg. These tablets combine two active ingredients, amlodipine besylate (a calcium channel blocker) and atorvastatin calcium (an HMG CoA-reductase inhibitor). Amlodipine is used to treat hypertension and coronary artery disease. It works by lowering blood pressure to reduce the risk of cardiovascular events, primarily myocardial infarctions and strokes. Atorvastatin is used as an adjunct therapy to diet in the prevention of cardiovascular disease and hyperlipidaemia.

Esomeprazole is a proton pump inhibitor that reduces the amount of acid secreted by the stomach. It is used to reduce the risk of gastric ulcers, and in the treatment of gastroesophageal reflux disease and pathological hypersecretory conditions, including Zollinger-Ellison syndrome. It is also used to eradicate Helicobacter pylori to reduce the risk of duodenal ulcer recurrence.

These recently approved products will all be manufactured at Zydus’ manufacturing facilities in Ahmedabad, India.

Related article
Generics manufacturers increase investment in injectables

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010